FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug
mohamed_hassan / Pixabay

FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug

According to a press release from Maryland-based Viela Bio, the US Food and Drug Administration (FDA) recently agreed to review the Company's Biologics License Application for its neuromyelitis optica spectrum…

Continue Reading FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug
FDA Approves Soliris for Treatment of Neuromyelitis Optica Spectrum Disorder
source: pixabay.com

FDA Approves Soliris for Treatment of Neuromyelitis Optica Spectrum Disorder

According to a publication at Markets Insider, the Food and Drug Administration (FDA) recently approved Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder. The approval marks the first…

Continue Reading FDA Approves Soliris for Treatment of Neuromyelitis Optica Spectrum Disorder